Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by Ingiboyon Jan 01, 2023 12:33pm
121 Views
Post# 35198976

RE:End of 2022

RE:End of 2022
Genie29j wrote:

Well, it's been another brutal year. Replicel closed at 5¢ to end the 2022 year. 

While this is certainly another blow to our "investment", I trust that Andrew and the outcome of the Shiseido trial are our last two hurrahs.. both will have a runway of about 8 months. 

Nervous? Thoughts? 


let's hope we end 2023 on a better note! Here's to a year end close price of $3-4.00 

Cheers 



Yes, let's hope that 2023 is the year that us long term investors finally see the return we have been patiently waiting for.
 I re-read the Corporate Update from late November and in it are some interesting forshadowing.
Under Financing:
"RepliCel remains in talks with multiple investors, current and new, and is witnessing increased interest."

This latest tweet from Dec. 19th:
"We just arrived in Japan! We are meeting with multiple potential investors and partners for all of our products."

For Andrew Schutte to fly to Japan there must be a strong probability of landing a major investor. What type of investor ?  Strictly injecting money for shares or possibly a much larger investor interested in taking on RCH-01 in the eventuality that Replicel wins the Arbitration with Shiseido.This new "mega" investor may also want to be the distributor for Dermaprecise in Japan.

Yes my imagination is running wild but who knows.   I imagine that over the next week there will be some sort of update on this trip to Japan.







<< Previous
Bullboard Posts
Next >>